APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
| Application |
Recommended Dilution |
| 0.5 - 1 μg/mL |
| 5 μg/mL |
| Assay dependent |
Not tested in other applications.
Calculated MW
Positive Control
Human Brain Tissue Slide(GTX22203) , Rat Brain Tissue Lysate(GTX27942)
Product Note
Numerous isoforms of CAPS1 are known to exist; the lower molecular weight bands seen in the immunoblot image are likely to be these isoforms. This CAPS1 antibody is predicted to be specific to CAPS1 and not recognize CAPS2.
PROPERTIES
Form
Liquid
Buffer
PBS
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
CAPS1 antibody was raised against a 20 amino acid synthetic peptide near the carboxy terminus of the human CAPS1.The immunogen is located within the last 50 amino acids of CAPS1.
Purification
Purified by antigen-affinity chromatography
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
calcium dependent secretion activator , CADPS1 , CAPS , CAPS1 , UNC-31
Cellular Localization
Cell junction, synapse
Background
CAPS1 and its related protein CAPS2 encode novel neural/endocrine-specific cytosolic and peripheral membrane proteins. Both are essential components of the synaptic vesicle priming machinery and are required for the Ca2+-regulated exocytosis of secretory vesicles; CAPS-deficienct neurons contain no or very few fusion competent synaptic vesicles, causing a selective impairment of fast phasic transmitter release. CAPS1 acts at a stage in exocytosis that follows ATP-dependent priming, which involves the essential synthesis of phosphatidylinositol 4,5-bisphosphate and is thought to be a specific regulator of large dense-core vesicle fusion. Numerous isoforms of CAPS1 are known to exist; the lower molecular weight bands seen in the immunoblot image are likely to be these isoforms. This CAPS1 antibody is predicted to be specific to CAPS1 and not recognize CAPS2.
Database
Research Area
DATA IMAGES
|
GTX85037 IHC-P Image
IHC-P analysis of human brain tissue using GTX85037 CAPS1 antibody.
Working concentration : 20 μg/ml
|
|
|
GTX85037 IHC-P Image
IHC-P analysis of human brain tissue using GTX85037 CAPS1 antibody.
Working concentration : 5 μg/ml
|
|
|
GTX85037 WB Image
WB analysis of rat brain tissue lysate using GTX85037 CAPS1 antibody.
Working concentration : (A) 0.5 and (B) 1 μg/ml
|
REFERENCE
There are currently no references for CAPS1 antibody (GTX85037). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for CAPS1 antibody (GTX85037). Be the first to share your experience with this product.
